Olympus Acquires Israeli Medical Device Company Medi-Tate to Drive Global Urology Business Growth
Olympus Corporation (”Olympus” – Director, Representative Executive Officer, President and CEO: Yasuo Takeuchi) announced today that it has finalized the acquisition of Israeli medical device company Medi-Tate Ltd. (“Medi-Tate” – CEO: Ido Kilemnik) following the announcement of its decision to exercise the call option in February, 2021. Through this acquisition, Olympus expands its business line in offering in-office treatment for benign prostatic hyperplasia (BPH) treatment and solidifies its position as a leader in the field of urological devices.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210527005341/en/
iTind is the newest addition to the portfolio of Olympus, a market leader in devices for BPH treatment. (Graphic: Business Wire)
Medi-Tate is a medical device manufacturer engaged in the research and development, production, and sale of devices for the minimally invasive treatment of BPH. The company’s flagship product “iTind” has received U.S. FDA de Novo authorization and a European CE mark. With its initial Medi-Tate investment, Olympus has had the right of distribution since November 2018.
The incidence of BPH, one of the most common diseases in aging men and the most common cause of lower urinary tract symptoms (“LUTS”), is expected to increase as the general global population gets older. According to the American Urological Association, BPH is a condition that nearly 80% of men will face in their lifetime and that ratio is higher in older ages.ⅰ Medication and surgical treatment have been among the usual treatment options for BPH, and in recent years, more minimally invasive surgical treatment devices have come to the market.
Olympus is a market leader providing devices for BPH treatment such as resectoscopes and a wide variety of electrodes. By adding the non-ablative BPH treatment device iTind, which allows patients to maintain their sexual function, to its portfolio, Olympus can provide urologists more treatment options according to the symptoms and needs of their patients, ranging from in-offices day treatment to surgical therapies in hospitals.
Nacho Abia, Chief Operating Officer of Olympus Corporation, said, “the acquisition of Medi-Tate aligns with our corporate strategy of focusing on three priority therapeutic areas within our Therapeutic Solutions Division — gastroenterological endotherapy devices, urological devices and respiratory endotherapy devices. Medi-Tate’s innovative products offer a truly minimally invasive treatment option for patients and flexibility in the delivery of care for healthcare professionals.”
Ido Kilemnik, Chief Executive Officer of Medi-Tate, commented, “We believe Olympus appreciates our focus on long-term clinical results and dedication of the entire Medi-Tate team. We are pleased to be joining Olympus, which shares our vision of making iTind the global standard for BPH treatment. We are excited to be collaborating with Olympus in our effort to enhance the patients’ quality of life.”
Minimally invasive treatment enabled by iTind
iTind, a temporarily implanted nitinol device, supports the relief of lower urinary tract symptoms (LUTS) due to BPH. The iTind treatment is performed by an urologist in an outpatient hospital, ambulatory surgery center or in a physician’s office, where the iTind device is placed in the prostate in a folded configuration. The device slowly expands and exerts gentle pressure at three precise points to reshape the prostatic urethra and bladder neck. After five to seven days, the device is completely removed, leaving a wider opening through which urine can flow for the relief of BPH symptoms.
i American Urological Association, Benign Prostatic Hyperplasia. Available at:
Medi-Tate is an Israeli medical device company dedicated to improving men’s healthcare and quality of life via effective, non-surgical solutions for Benign Prostatic Hyperplasia (BPH). The flagship iTind treatment for BPH currently has the EU CE Mark and is approved for sale in the European Union, UK, Israel, Australia, Brazil, and the FDA cleared for use in the United States. For more information, visit www.medi-tate.com.
AboutOlympus’ Therapeutic Solutions business
In its Therapeutic Solutions business, Olympus uses innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic, and minimally invasive procedures to improve clinical outcomes, reduce overall costs, and enhance the quality of life for patients and their safety. Starting with its early contributions to the development of the polypectomy snare, Olympus’ Therapeutic Solutions portfolio has grown to include an array of surgical energy devices and a wide range of instruments to help prevent, detect, and treat disease. For more information, visit www.olympus-global.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
For questions or additional information:
Europe, Middle East and Africa
Japan and APAC
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Brings Flagship Features to Broader Smartphone Market with LPDDR5 Multichip Package15.6.2021 10:00:00 CEST | Press release
Samsung Electronics Co., Ltd., the world leader in advanced memory technology, today announced that it has begun mass producing its latest smartphone memory solution, the LPDDR5 UFS-based multichip package (uMCP). Samsung’s uMCP integrates the fastest LPDDR5 DRAM with the latest UFS 3.1 NAND flash, delivering flagship-level performance to a much broader range of smartphone users. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210615005507/en/ Samsung's uMCP with industry’s highest performance, capacity and efficiency for 5G applications (Photo: Business Wire) “Samsung’s new LPDDR5 uMCP is built upon our rich legacy of memory advancements and packaging know-how, enabling consumers to enjoy uninterrupted streaming, gaming and mixed reality experiences even in lower-tier devices,” said Young-soo Sohn, vice president of the Memory Product Planning Team at Samsung Electronics. “As 5G-compatible devices become more mainstream, we
Startups from 21 Countries Showcase Deep Tech Innovations at #InnoVEXVirtual15.6.2021 09:23:00 CEST | Press release
Startups are the key to technology development, and they are the driver for industry transformations and evolutions. In COMPUTEX 2021 Virtual, the event organizer, TAITRA, has dedicated a special hall for #InnoVEXVirtual. With 81 startups from 21 countries, TAITRA aims to empower these startups by bridging the network and business opportunities with them and the global technology ecosystem through the digital platform. Sparking creativity with global disruptors Since its first establishment in 2016, InnoVEX, the exhibit dedicated to startups at COMPUTEX, has successively hosted National Pavilions from France, Korea and the Netherland. The National Pavilions have become one of the exhibition highlights to the visitors, venture capitalists and media. This year, La French Tech Pavilion, organized by Business France, gathers 5 teams to showcase tech strength and diversity from France in the fields including Quantum Computing as a Service, Organic Photovoltaic, Wireless Charging, Processing
MACIF’s Successful Euro 1,75 bn Issuance Attracted Huge Appetite From European Investors15.6.2021 09:05:00 CEST | Press release
MACIF, Aéma Groupe’s affiliate, announces the successful issuance of a multi-tranche €1.75bn subordinated debt issuance comprising: - a €400mn Perpetual Non-Call 2029 Restricted Tier 1 fixed resettable rate notes bearing interest at an initial fixed rate of 3.50% until the first call date and expected to be rated Ba1 by Moody’s - a €850mn 2052 Non-Call 2032 Tier 2 fixed to floating rate notes bearing interest at an initial fixed rate of 2.125% until the first call date and expected to be rated Baa1 by Moody’s - a €500mn 2027 Tier 3 notes bearing interest at a 0.625% fixed rate coupon and expected to be rated Baa1 by Moody’s MACIF has met with over 85 institutional investors over phone calls which took place from 8th to 11th June 2021 in order to present the Group’s credit. With more than 400 investors participating into the multi-tranche transaction for a total book size over €12.1bn, this represents the first Euro triple-tranche subordinated from a European insurer. The three days of
Aragen Announce Multi-Year Partnership With FMC Corporation, Aims at Accelerating Agro-Chemical Pipeline15.6.2021 09:03:00 CEST | Press release
Aragen Life Sciences (formerly, GVK BIO), a leading Contract Research and Development Organization (CRDO), head quartered out of Hyderabad, India, announced a strategic partnership with FMC Corporation, a global leader in innovative agricultural science, that provides solutions towards crop protection, plant health, and professional pest and turf management. Through this collaboration, Aragen will support FMC’s global discovery and development needs, including discovery chemistry, discovery biology, and chemical process development. This partnership is focused on accelerating FMC Corporation’s agro-chemical pipeline. “It has been our privilege to have been able to assist FMC, one of the global leaders in crop science, accelerate its R&D, through this long term partnership. The expansion of this collaboration through all facets of discovery and development is a testimony to the trust and confidence that FMC has in Aragen - we look forward to driving several more success stories for our
KeyBank Goes Live With SmartStream’s Cloud Collateral Management Solution15.6.2021 09:00:00 CEST | Press release
SmartStream Technologies, the financial Transaction Lifecycle Management (TLM®) solutions provider, today announces KeyBank N.A. goes live with its TLM Collateral Management (formerly Algorithmics/IBM Collateral) OnDemand solution - offering coverage for cleared and non-cleared, over the-counter (OTC) derivatives, repo and securities lending margining. KeyBank needed to streamline its back-office workflow with a cloud offering that would enhance efficiencies within their collateral management operations - this included all data capture, validation, calculation and processing. In addition, the use of APIs links the application to various other reporting solutions and downstream systems. A powerful user interface provides clear and logical paths for the user, and a management dashboard will help with trend analysis and decision-making. Paula Janofsky, Swap Operations Director, KeyBank, states: “Moving to the cloud enabled us to further improve and automate our operational and credit risk
Polymateria Awarded as Technology Pioneer by World Economic Forum15.6.2021 09:00:00 CEST | Press release
Polymateria, the London-based British tech company that last year produced the world’s first fully recyclable and biodegradable plastic, was selected among hundreds of candidates as one of the World Economic Forum’s “Technology Pioneers”. Polymateria came through Imperial College London’s incubator system and counts a diverse portfolio of customers and partners from Indorama Ventures, to Hollywood Actress Robin Wright, purposeful auto racing Extreme E, Rolling Loud Festivals, DAZN Sports TV network and the Indian Government. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210615005173/en/ The World Economic Forum’s Technology Pioneers are early to growth-stage companies from around the world that are involved in the use of new technologies and innovation that are poised to have a significant impact on business and society. With their selection as Technology Pioneer, CEO Niall Dunne of Polymateria will be invited to participat
c-LEcta exceeds EUR 10 million in revenue with significantly higher EBITDA15.6.2021 09:00:00 CEST | Press release
c-LEcta, a global biotechnology company with technology leadership in enzyme engineering and bioprocess development, managed to successfully continue its growth in the fiscal year 2020 despite a challenging year overall. Revenue increased to EUR 10.4 million, while EBITDA rose sharply to EUR 2.0 million. The continued growth of the product business was an important factor in the continued growth of revenue. The good development in the first quarter of 2021 allows the management to look ahead to the current year with optimism. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210615005102/en/ The c-LEcta management team (from left to right Thomas Pfaadt, CFO, Carsten Fietz, Senior Vice President Finance and Administration, Dr. Marc Struhalla, Founder and CEO) Image: c-LEcta c-LEcta managed to grow strongly once again in 2020. Despite a generally challenging economic environment, revenue in the past fiscal year rose by 14% to EUR
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom